CYP2C9 and Decreased liver function: Isberner et al. allocated the reduced clearance to further DDI caused by a combination of several moderate and weak CYP3A4 or CYP2C9 inhibitors (e.g., atorvastatin and amiodarone) and changes in hepatic clearance due to liver dysfunction, which is, however, hypothetical.